|
| | | | AUDITORIUM | 08:30 - 10:30 ORAL PRESENTATION SESSION 1 ? DRIVING UNDER THE INFLUENCE I | | | | | Chan-Hosokawa EVALUATION OF DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS IN DUID INVESTIGATION CASES AND CONSEQUENCES OF VARIOUS THC PER SE THRESHOLDS. |
| | | | |
| | | | Smink B. GHB IN SUSPECTED IMPAIRED DRIVERS IN THE NETHERLANDS AND A COMPARISON WITH POSTMORTEM CASES. |
| | | | |
| | | | Officer J. PREVALENCE OF NEW PSYCHOACTIVE SUBSTANCES IN DRUG DRIVERS IN SCOTLAND - A 2 YEAR REVIEW |
| | | | |
| | | | Drummer O. CRASH RISK OF MEDICINAL DRUGS |
| | | | |
| | | | Lemos N. P. DRIVING UNDER THE INFLUENCE OF MARIJUANA VERSUS DRIVING AND DYING UNDER THE INFLUENCE OF MARIJUANA: A COMPARISON OF BLOOD CANNABINOID CONCENTRATIONS IN ARRESTED DRIVERS VERSUS DECEASED DRIVERS |
| | | | |
| | | | Schallmach E. DRIVING UNDER THE INFLUENCE OF ALCOHOLAMONG CAR DRIVERS IN ISRAEL |
| | | | |
| | | | Telving R. IS THC-COOH-GLUCURONIDE A USEFUL MARKER FOR TETRAHYDROCANNABINOL (THC) IN DUID CASES? RETROSPECTIVE DATA ANALYSIS ON UPLC-HR-TOFMS DATA FILES FROM 2 YEARS OF DUID CASES |
| | | | |
| | | | Zancanaro F. DRIVING UNDER THE INFLUENCE OF ALCOHOL AND ILLICIT DRUGS. A FIVE-YEAR STUDY ON 6500 DRIVERS INVOLVED IN ROAD ACCIDENTS IN NORTH-EAST ITALY |
| | | | |
| |
11:00 - 13:00 ORAL PRESENTATION SESSION 2 - ANTIDOPING | | | | | Botre F. LIPOSOMES AS DRUG DELIVERY SYSTEMS IN SPORT DOPING: RECENT ADVANCES IN THE STUDY OF LIPOSOME VEHICULATED HEMOGLOBINS |
| | | | |
| | | | Görgens C. "DILUTE-AND-INJECT" MULTI-TARGET SCREENING ASSAY FOR (NOVEL) HIGHLY POLAR DOPING AGENTS USING HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY HIGH RESOLUTION/HIGH ACCURACY MASS SPECTROMETRY FOR SPORTS DRUG TESTING. |
| | | | |
| | | | Richards S. L. APTAMER BASED DETECTION OF PEPTIDE AND PROTEIN DOPING THREATS IN SPORT USING GONADOTROPIN-RELEASING HORMONE AND ERYTHROPOIETIN AS MODEL COMPOUNDS |
| | | | |
| | | | Vogel M. ISOLATION, ENRICHMENT AND DETECTION OF ERYTHROPOIETIN MIMETIC AGENTS FROM HUMAN URINE BY MEANS OF EPO-RECEPTOR-PURIFICATION AND LC-HR-MS/MS DETERMINATION |
| | | | |
| | | | Thevis M. FULL-LENGTH MGF AND XENON - NEW ADDITIONS TO ANTI-DOPING TEST PROGRAMS |
| | | | |
| | | | Dib J. ADIPOR AGONISTS AND THEIR IMPLEMENTATION IN SPORTS DRUG TESTING |
| | | | |
| | | | Walpurgis K. MYOSTATIN INHIBITORS IN SPORTS DRUG TESTING: DETECTION OF MYOSTATINNEUTRALIZING ANTIBODIES IN PLASMA SAMPLES BY USING IMMUNOAFFINITY PURIFICATION AND WESTERN BLOTTING |
| | | | |
| | | | Salomone A. INNOVATIVE CHEMOMETRIC APPROACHES AS POWERFUL TOOLS IN THE ATHLETE BIOLOGICAL PASSPORT |
| | | | |
| | | | Palermo A. DRUG-DRUG INTERACTIONS AND MASKING EFFECTS IN SPORT DOPING: THE CONTRIBUTION FROM IN VITRO STUDIES COUPLED TO CHROMATOGRAPHY-MASS SPECTROMETRY |
| | | | |
| |
14:30 - 16:00 ORAL PRESENTATION SESSION 3 ? TOXICOKINETICS III | | | | | Kikura-Hanajiri R. EVALUATION OF THE BINDING AFFINITIES OF 54 NEWLY-EMERGED SYNTHETIC CANNABINOIDS AT THE CANNABINOID CB1 AND CB2 RECEPTORS |
| | | | |
| | | | Heß C. CB1 AND CB2 RECEPTOR AFFINITIES OF SYNTHETIC CANNABINOIDS ON THE ILLICIT DRUG MARKET |
| | | | |
| | | | Steuer A. E. CYP2D6 GENOTYPE-DEPENDING CHIRAL PHARMACOKINETICS AND PHASE I AND II METABOLISM OF MDMA AFTER CO-ADMINISTRATION OF BUPROPION IN A CONTROLLED STUDY IN HUMANS |
| | | | |
| | | | Høiseth G. HEROIN KINETICS IN BLOOD AND VITREOUS HUMOR IN A LIVING PIG MODEL |
| | | | |
| | | | Gunja N. SEROTONIN TOXICITY AND CYTOCHROME P450 GENETIC POLYMORPHISMS |
| | | | |
| | | | Swortwood M. FIRST METABOLIC PROFILE OF PV8, A NOVEL SYNTHETIC CATHINONE, BY HIGHRESOLUTION MASS SPECTROMETRY (HRMS) |
| | | | |
| | | | Huppertz L. FLUBROMAZOLAM - CHARACTERIZATION AND BASIC PHARMACOKINETIC EVALUATION OF A HIGHLY POTENT DESIGNER BENZODIAZEPINE |
| | | | |
| |
16:30 - 18:00 ORAL PRESENTATION SESSION 4 ? TOXICOKINETICS IV | | | | | Fonseca S. SEQUENCING CYP2D6 IN POST-MORTEM BLOOD SAMPLES WITH HIGH CONCENTRATION OF TRAMADOL FOR THE DETECTION OF *3, *4, *6, *8, *10 AND *12 ALLELES |
| | | | |
| | | | Desharnais B. POSTMORTEM IDENTIFICATION OF METABOLIZER TYPE: A PROTEOMICS APPROACH |
| | | | |
| | | | Hlo?ek T. CANNABINOID PHARMACOKINETIC AND BEHAVIOURAL PROFILES AFTER DIFFERENT ROUTES OF ADMINISTRATION IN RATS |
| | | | |
| | | | Hartman R. L. CONTROLLED VAPORIZED CANNABIS, WITH AND WITHOUT ALCOHOL: SUBJECTIVE EFFECTS AND BLOOD CANNABINOID DISPOSITION |
| | | | |
| | | | Mehling L. M. GHB AND ITS NEWLY DESCRIBED METABOLITE GHB-?-O-D-GLUCURONIDE ? DISCRIMINATION EXOGENOUS/ENDOGENOUS VIA LC/MS/MS AND GC/C/IRMS |
| | | | |
| | | | Malta G. BEHAVIOURAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL CANNABIMIMETIC ADAMANTANE-DERIVED INDOLE, APICA, AND CONSIDERATIONS ON THE POSSIBLE MISUSE AS A PSYCHOTROPIC SPICE ABUSE, IN C57BL/6J MICE |
| | | | |
| |
|
| | | | |
| | | | AUDITORIUM | 08:45 - 09:00 WELCOME INTRODUCTION | | | | | Donata Favretto Welcome Introduction |
| | | | |
| |
09:00 - 09:30 FIRST LECTURE | | | | | Giovanni SERPELLONI "Addiction Neuroscience and Toxicology: a new opportunity" |
| | | | |
| |
09:30 - 11:00 ORAL PRESENTATION SESSION 1 ? TOXICOKINETICS I | | | | | Meyer M. R. TOXICOKINETICS OF NEW PSYCHOACTIVE SUBSTANCES: DETERMINATION OF THEIR PLASMA PROTEIN BINDING AND ITS USE IN CALCULATING METABOLIC STABILITY |
| | | | |
| | | | Richter L. H. J. CROCODILE: METABOLISM OF DESOMORPHINE IN HUMAN LIVER MICROSOMES, HUMAN HEPATOCYTE CULTURES, AND RAT URINE AS WELL AS ITS DETECTABILITY USING STANDARD URINE SCREENING APPROACHES |
| | | | |
| | | | Mardal M. STUDIES ON THE STABILITY OF COCAINE, MDMA, MDEA, AND THEIR MAIN HUMAN URINARY METABOLITES IN WASTEWATER BY HILIC LC-MS/MS, USING POOLED HUMAN URINE AND URINATED SOIL SAMPLES |
| | | | |
| | | | Vevelstad M. METABOLISM OF THE DESIGNER DRUG PMMA (4-METHOXYMETHAMPHETAMINE) IN HUMAN LIVER MICROSOMES |
| | | | |
| | | | Franz F. METABOLISM OF SYNTHETIC CANNABINOIDS - SIMILARITIES AND DIFFERENCES BETWEEN METABOLIC PATTERNS OF DIFFERENT STRUCTURAL SUBCLASSES |
| | | | |
| | | | Watanabe S. METABOLIC STUDIES OF SYNTHETIC CANNABINOID PB-22 BY CUNNINGHAMELLA ELEGANS |
| | | | |
| | | | Zidkova M. STUDY ON BEHAVIORAL AND PHARMACOKINETIC PROPERTIES OF 5,6-METHYLENEDIOXY- 2-AMINOINDANE (MDAI) INCLUDING BIOTRANSFORMATION IN RATS AFTER A SUBCUTANEOUS BOLUS DOSE |
| | | | |
| |
11:30 - 13:00 ORAL PRESENTATION SESSION 2 ? ALCOHOL USE MARKERS | | | | | Wilde M. ETHYL 4-HYDROXYBUTYRATE ? SEARCH FOR A LONG-TERM MARKER OF COMBINED GAMMA-BUTYROLACTONE (GBL) AND ALCOHOL UPTAKE |
| | | | |
| | | | Skopp G. FORMATION AND INHIBITION OF ETHYL GLUCURONIDE AND ETHYL SULFATE |
| | | | |
| | | | Schroeck A. DEVELOPMENT OF A STANDARDISED TEST FOR THE ACTIVITY OF THE ENZYME PHOSPHOLIPASE D (PLD), RESPONSIBLE FOR BIOSYNTHESIS OF THE ALCOHOL BIOMARKER PHOSPHATIDYLETHANOL (PETH) |
| | | | |
| | | | Beck O. OBSERVATIONS ON THE SAMPLING OF NON-VOLATILES IN EXHALED BREATH ? DETECTION OF PHOSPHATIDYLETHANOL |
| | | | |
| | | | Boettcher M. AUTO-BREWERY SYNDROME AS A POSSIBLE EXPLANATION FOR INCREASED ALCOHOL BIOMARKERS? |
| | | | |
| | | | Vaiano F. A NOVEL, SIMULTANEOUS EXTRACTION OF FAEE AND ETG FROM MECONIUM AND ANALYSIS BY LC-MS/MS |
| | | | |
| | | | Morini L. KINETICS OF ETG IN FINGERNAILS IN A GROUP OF CHRONIC HEAVY DRINKERS |
| | | | |
| |
14:30 - 16:00 ORAL PRESENTATION SESSION 3 ? NEW PSYCHOACTIVE SUBSTANCES (INTOXICATION CASES AND IDENTIFICATION) | | | | | Hisatsune K. DETERMINATION OF NEWLY ENCOUNTERED DESIGNER DRUGS ?-PHP AND ACETYLFENTANYL IN AN ACUTE INTOXICATION CASE BY LC/Q-TOFMS |
| | | | |
| | | | Pricone M. G. THREE DEATHS INVOLVING SYNTHETIC CANNABINOID- PB-22 (1-PENTYL-8-QUINOLINYL ESTER-1H-INDOLE-3-CARBOXYLIC ACID) |
| | | | |
| | | | Ewald A. DEATH AFTER CONSUMPTION OF NEW SYNTHETIC CANNABINOIDS AND ALCOHOL |
| | | | |
| | | | Liveri K. A FATAL INTOXICATION RELATED TO MDPV AND PENTEDRONE COMBINED WITH ANTI PSYCHOTIC AND ANTIDEPRESSANT SUBSTANCES IN CYPRUS |
| | | | |
| | | | Hockenhull J. MEPHEDRONE IN POST-MORTEM CASES: A 5 YEAR REVIEW |
| | | | |
| | | | Gerace E. DETECTION OF 31 STIMULANT, PSYCHEDELIC AND DISSOCIATIVE DESIGNER DRUGS IN REAL HAIR SAMPLES |
| | | | |
| | | | Strano Rossi S. METHODS DEVELOPMENT FOR THE ASSESSMENT OF NPS USE BY ANALYSIS OF DIFFERENT BIOLOGICAL SAMPLES: HAIR, BLOOD AND URINE |
| | | | |
| |
16:30 - 18:00 ORAL PRESENTATION SESSION 4 - TOXICOKINETICS II | | | | | Watanabe K. METABOLISM OF MAJOR PHYTOCANNABINOIDS BY HUMAN PLACENTA MICROSOMES AND CYP19 |
| | | | |
| | | | Wohlfarth A. METABOLISM OF 25I-NBOME AND 25C-NBOME, TWO SYNTHETIC HALLUCINOGENS, IN MICE AND CORRELATION WITH AUTHENTIC HUMAN URINE SAMPLES |
| | | | |
| | | | Knoop A. IN VITRO METABOLISM STUDIES AND LC-MS CHARACTERIZATION OF SARM LG121071 FOR ROUTINE DOPING CONTROL |
| | | | |
| | | | Steuer A. E. , Boxler M. INHIBITION POTENTIAL OF MDMA AND ITS RELEVANT METABOLITES ON THE IN VITRO DEAMINATION OF SEROTONIN AND DOPAMINE |
| | | | |
| | | | Schaefer N. PHARMACOKINETIC MODELLING OF JWH-210, RCS-4, AND THC IN PIG SERUM AFTER INTRAVENOUS ADMINISTRATION |
| | | | |
| | | | Ross Jornil J. THE USE OF CYTOCHROME P450 2D6 AND 2C19 GENOTYPING FOR TOXICOLOGICAL INTERPRETATION OF SPECIAL FORENSIC CASES ? USEFUL OR NOT? |
| | | | |
| | | | Haage P. ENANTIOSELECTIVE PHARMACOKINETICS OF TRAMADOL AND ITS THREE MAIN METABOLITES; IMPACT OF CYP2D6 AND CYP2B6 GENOTYPE |
| | | | |
| |
|
| | | | |
|
|